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AbstrAct
Objectives To characterise the use of the 
parenteral non-steroidal anti-inflammatory 
drug parecoxib when given by continuous 
subcutaneous infusion (CSCI) in a hospice 
population. Clinical experience suggests 
parecoxib CSCI may be of benefit in this 
population, but empirical evidence in relation to 
its safety and efficacy is lacking.
Methods Retrospective chart review of patients 
with a cancer diagnosis receiving parecoxib CSCI 
from 2008 to 2013 at the Marie Curie Hospice, 
Belfast. Data were collected on treatment 
regime, tolerability and, in patients receiving 
at least 7 days treatment, baseline opioid dose 
and changes in pain scores or opioid rescue 
medication requirements.
results Parecoxib CSCI was initiated in 80 
patients with a mean administration of 17.9 
days (median 11, range 1–94). When used 
for a period of 7 days, there was a statistically 
significant reduction in pain scores (p=0.002) 
and in the number of rescue opioid doses 
required (p=0.001), but no statistically significant 
opioid-sparing effect (p=0.222). It was generally 
well tolerated, although gastrointestinal, renal 
adverse effects and local site irritation were 
reported.
conclusions Parecoxib may have a valuable 
place in the management of cancer pain, 
especially towards the end of life when oral 
administration is no longer possible and CSCI 
administration is relied on. Further studies into 
the efficacy and tolerability of parecoxib CSCI are 
merited.
bAckgrOund
Non-steroidal anti-inflammatory drugs 
(NSAIDs) are non-opioid analgesics 
recommended for regular use in the 
WHO analgesic ladder for mild to 
moderate pain.1 NSAIDs vary in their 
adverse effect profile with those showing 
selective inhibition of cyclo-oxygenase-2 
(COX-2) displaying less gastrointestinal 
adverse effects.2 Parecoxib, a prodrug 
of valdecoxib, is an injectable selective 
COX-2 inhibitor marketed in the UK as 
Dynastat Injection by Pfizer Limited. It 
is licensed for the short-term treatment 
of postoperative pain in adults by the 
intramuscular or intravenous routes.3 It 
has been used extensively by continuous 
subcutaneous infusion (CSCI) in pallia-
tive care in Northern Ireland; however, 
evidence for its safety and efficacy by this 
route is lacking.
AiM Of the study
This study aims to:
1. retrospectively record the usage and 
tolerability of CSCI parecoxib in patients 
with advanced cancer at Marie Curie 
Hospice, Belfast
2. investigate if CSCI parecoxib was 
associated with a reduction in pain scores 
at any time, or when given for minimum 
7 days: (1) reduction in background opioid 
dose and (2) reduction in frequency of 
opioid rescue medication doses.
 
MethOd
All inpatients prescribed CSCI pare-
coxib from 2008 to 2013 were identified 
from pharmacy records. Patients with a 
non-cancer diagnosis or admitted already 
receiving parecoxib CSCI were excluded. 
A retrospective chart review was under-
taken to collect data from the medical 
notes on patient demographics, medical 
history, baseline medication, parecoxib 
dose, duration, diluent, volume of infu-
sion and adverse effects. For patients 
receiving at least 7 days of CSCI pare-
coxib, background opioid (converted 
to oral morphine equivalence using 
regional conversion tables) and rescue 
opioid use were recorded, and a one-way 
repeated measures analysis of variance 
was applied. Where recorded, pain scores 
(0–10 Numerical Pain Rating Scale) were 
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documented, and a Wilcoxon signed-rank test was 
used. As this study was a service evaluation, ethical 
approval was not sought; however, the study method-
ology was reviewed and approved by the Marie Curie 
Hospice Belfast Research Group.
results
Eighty patients were identified, 46 males (57%) and 34 
females (43%). Mean age was 62 years (range 36–79 
years, SD 10.9). The most common cancer diagnoses 
were lung (20%), colorectal (13.8%), prostate (11.3%) 
and breast (10%).
The indications were metastatic bone pain 44/80 
(55%); non-malignant pain 13/80 (16.3%); mixed pain 
including metastatic bone with another pain 10/80 
(12.6%); visceral pain 5/80 (6.3%) and unknown 
8/80 (10%). Twenty-eight (35%) patients switched 
to parecoxib CSCI from various oral NSAIDs, 3/80 
from ketorolac or diclofenac CSCI and 5/80 from 
topical NSAIDs. Sixty-two patients (77.5%) received 
CSCI parecoxib for at least 7 days. Gastroprotection 
was coprescribed in 74/80 patients, most commonly a 
proton pump inhibitor (72/80).
dose and administration (see figure 1)
After initial dosing, 36 (45%) patients had a dose 
increase, 35 (43.8%) no dose change, 5 (6.3%) a 
decrease and 4 (5%) an increase then subsequent 
decrease. Mean duration of treatment was 17.9 days 
(median 11, range 1-94). Parecoxib was administered 
alone apart from two patients where it was combined 
with dexamethasone 500 µg. Sodium chloride 0.9% 
was the diluent in 78/80 patients. Water for injection 
was used in 2/80, but both were subsequently switched 
to sodium chloride 0.9% due to local site irritation. 
Mean total volume was 11.9 mL (range 9–22 mL, SD 
2.6). Patients who developed local site reactions had a 
mean volume of 11.7 mL versus 12 mL for those not 
experiencing such effects. All diluted solutions were 
visually compatible. Thirty-seven patients continued 
parecoxib CSCI until death in the hospice with 19/80 
(24%) discharged on parecoxib and the clinical deci-
sion made to stop in the remainder. Reasons for stop-
ping included adverse effects (12/80), switching to oral 
NSAID (7/80) and lack of efficacy (5/80).
Adverse effects
Forty per cent (32/80) of patients had at least one 
adverse effect recorded in the medical notes (table 1). 
The maximum number of adverse effects in a single 
patient was two. One patient reported both dyspepsia 
and haematemesis.
Opioid dose
Fifty patients (63%) were coadministered CSCI 
opioids, 20/80 (25%) regular oral opioids, 4/80 
(5%) transdermal opioids, one intrathecal opioid and 
5% (4/80) received no regular opioid. Of the 62/80 
patients receiving at least 7 days CSCI parecoxib and 
concurrent regular opioid medication, the mean oral 
figure 1 Parecoxib CSCI dosing. The median starting dose was 40 mg and the majority of patients had a maximum and final dose 
of 60 mg or less.
Table 1 Adverse effects reported in medical notes (n=80)
Adverse effect Incidence
Resulted in 
parecoxib 
discontinuation
Local site reactions 15 1
Reduction in renal function 11 3
Dyspepsia 8 2
Haematemesis 2 2
Malaena 2 2
GI perforation 1 1
Rash 1 1
Itch 1 – 
Total 41 12
GI, gastrointestinal.
group.bmj.com on November 15, 2017 - Published by http://spcare.bmj.com/Downloaded from 
3Armstrong P, et al. BMJ Supportive & Palliative Care 2017;0:1–5. doi:10.1136/bmjspcare-2017-001348
Short report
morphine equivalent (MME) background opioid dose 
was 258 mg on day 1 and 240 mg on day 7. This reduc-
tion was not statistically significant (p=0.222). Fifty-
eight of the 62 patients also received rescue opioid 
doses, and there was a statistically significant reduction 
in mean number of rescue opioid doses per day from 
1.88 on day 1 to 1.22 on days 6 and 7 (p=0.001).
Pain scores
Only 16/80 (20%) of patients had pain scores recorded 
on day 1 and at least one other day from days 2–7. 
Median pain scores reduced from 7 on day 1 (IQR 
5–8) to 4 on the ‘final day pain score’ (IQR 2–6), which 
was a statistically significant change (Z=−3.154, 
p=0.002).
discussiOn
Parecoxib is licensed for the short-term treatment of 
postoperative pain by intravenous or intramuscular 
injection3 and has been given by daily subcutaneous 
injection for cancer pain.4 In our study of CSCI use, 
bone pain was the most frequent documented indica-
tion, involving 54/72 (75%) patients. This is in keeping 
with recorded use of diclofenac and ketorolac CSCI,5–8 
the other parenteral NSAIDS commonly used within 
palliative care. The licenced maximum daily dose of 
parecoxib is 80 mg. In our study, the most common 
starting dose was 40 mg and 62/80 (78%) had a final 
CSCI dose of 60 mg or less. Three patients received 
above 80 mg daily, although local practice now dictates 
a maximum of 80 mg/day, including ‘as required’ use, 
is generally adhered to.
Studies on postoperative parecoxib and a 
meta-analysis of NSAIDs in cancer pain both 
demonstrated an opioid-sparing effect not seen in 
our study.9 10 However, with over a third of our 
patients previously taking oral or parenteral NSAID, 
this may reflect one of the challenges with our retro-
spective methodology.
While over one-third of adverse effects were local 
site reactions, the overall incidence (18.8%) is compa-
rable with other CSCI studies.11 Such comparisons are 
challenging due to different reporting methods, with 
the rate for CSCI ketorolac site reactions in the liter-
ature ranging from 0% to 70%.5–7 Simple non-drug 
measures such as using different giving sets or changing 
the administration site more frequently have been 
recommended to reduce site reaction incidence.11 12 
The mean total volume was 11.9 mL but, as a result of 
the study, our standard practice has changed. We now 
dilute parecoxib CSCI to 22 mL using sodium chloride 
0.9%. This maximises dilution and avoids using water 
for injection (which is hypotonic) to reduce local site 
reactions.12
After discounting site reactions, the majority of 
adverse effects 24/26 (92%) were renal or gastrointes-
tinal, both commonly recognised with NSAID use.13 14 
These did not appear to be dose related. Most patients 
were coprescribed gastroprotection (recommended 
as standard practice for patients at risk of gastroin-
testinal ulceration, including the elderly15) and in 
the two cases of haematemesis, one had their gastro-
protective agent stopped due to diarrhoea while the 
other, with a history of gastrointestinal ulceration, had 
been taking oral meloxicam prior to parecoxib CSCI. 
The case of gastrointestinal perforation was managed 
conservatively with a short hospital admission. None 
of the gastrointestinal adverse effects identified 
were life threatening or required ongoing treatment. 
These results are lower than recorded in the largest 
study of CSCI ketorolac where four cases of gastro-
intestinal bleeding out of 36 patients were reported, 
despite receiving gastroprotection.7 However, the 
small numbers and methodology do not allow us to 
compare the two studies with any validity. Another 
study comparing intravenous ketorolac and parecoxib 
with placebo in healthy older adults  found no inci-
dence of gastrointestinal ulceration with parecoxib 
or placebo after endoscopy, while in those receiving 
intravenous ketorolac nearly a quarter had developed 
a gastrointestinal ulcer after 5 days.16
Of the 66 patients who had a repeat estimated 
glomerular filtration rate (eGFR) performed after 
starting parecoxib CSCI, 11 had a reduction in renal 
function, defined as eGFR below 60 or any reduction 
from baseline (where eGFR already less than 60). 
Of these, one had pre-existing impairment, four had 
already been taking an NSAID and three were on other 
nephrotoxic medicines. There were no cases where 
eGFR fell below 30, and only 3/11 patients had pare-
coxib CSCI discontinued as a precaution. Of note it is 
recognised that reduction in renal function in patients 
with advanced cancer towards the end of life is not 
uncommon.17
Parecoxib and valdecoxib, in common with other 
NSAIDs, are associated with an increased risk of 
cardiovascular events, after as early as 30 days treat-
ment in patients who have undergone coronary artery 
bypass grafting.18 They are also associated with unpre-
dictable but serious skin reactions which, combined 
with the cardiovascular risk, led to the withdrawal 
of valdecoxib from the European market in 2005.19 
No cardiovascular events were noted in our study, 
and the rash and itch seen were both self-limiting and 
possibly unrelated to parecoxib; however, this study 
was not sufficiently powered to accurately detect these 
effects. For all adverse effects, individual patient risk 
factors and likely duration of CSCI parecoxib should 
be considered. Towards the end of life, prescribers 
may feel the benefits of symptom control outweigh the 
potential risks of treatment.
strengths And weAknesses
The drawbacks of using retrospective chart reviews are 
well documented,20 and the challenges of locating and 
interpreting information from medical notes reduced 
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the study population. However, with the financial, 
ethical and logistical difficulties of prospective study 
design in palliative care noted, retrospective method-
ology is frequently used in hospice settings,21 and all 
apart from one of the current studies on CSCI NSAIDs 
use this methodology.
With only 20% of patients having a sufficient 
number of pain scores recorded to calculate benefit, a 
much larger sample would be needed to confirm this. 
While no significant reduction in MME was noted, the 
reduction in frequency of opioid rescue doses, which 
has been validated as an appropriate measure in pain 
research,22 was statistically significant. The clinical 
significance of this (1.88 in day 1 to 1.22 in days 6 
and 7) is difficult to confirm due to other confounding 
patient-related factors.
Given the complexity of prescribing and disease trajec-
tory of this patient population, the lack of a comparator 
group makes it difficult to reach definitive conclusions 
about CSCI parecoxib regarding efficacy and adverse 
effects. Other factors such as altering the regular opioid 
dose, coprescribing adjuvants and non-pharmacological 
interventions were also not recorded. However, with no 
published information available on CSCI parecoxib, this 
study is a first step to building up knowledge of this drug 
when used in a specialist palliative care population for 
cancer pain.
cOnclusiOns
This retrospective study demonstrated that parecoxib 
CSCI was both efficacious and generally well toler-
ated. Parecoxib could have a valuable place in the 
management of cancer pain, particularly bone pain 
and towards the end of life when oral administration 
is no longer possible. However, patient selection and 
assessment remains important to minimise significant 
adverse effects and the ongoing balance between risk 
and benefit in this population continues to require 
considered clinical approach.
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